- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eton Pharmaceuticals Inc (ETON)
Eton Pharmaceuticals Inc stock price live, this page displays NASDAQ ETON stock exchange data. View the ETON premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Eton Pharmaceuticals Inc real time stock price chart below.
What Is the Eton Pharmaceuticals Inc Stock Price Today?
The Eton Pharmaceuticals Inc stock price today is 15.390.
What Is the Stock Symbol for Eton Pharmaceuticals Inc?
The stock symbol for Eton Pharmaceuticals Inc is "ETON."
What Stock Exchange Does Eton Pharmaceuticals Inc Trade On?
Eton Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eton Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eton Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ETON quote. (ISIN: US29772L1089)
What Is the Eton Pharmaceuticals Inc Stock Price Today?
The Eton Pharmaceuticals Inc stock price today is 15.390.
What Is the Stock Symbol for Eton Pharmaceuticals Inc?
The stock symbol for Eton Pharmaceuticals Inc is "ETON."
What Stock Exchange Does Eton Pharmaceuticals Inc Trade On?
Eton Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Eton Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Eton Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ETON quote. (ISIN: US29772L1089)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.125
15.631
52 wk Range
11.087
23.000
ETON is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.12515.631
52 wk Range
11.08723.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ETON Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
30.000
Upside
+94.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Form 8K Eton Pharmaceuticals Inc For: 18 November
- Investing.com
- Form 144 Eton Pharmaceuticals For: 12 December
- Investing.com
- Form 8K Eton Pharmaceuticals Inc For: 4 December
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Eton Pharmaceuticals Inc Company Profile
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals Inc Earnings Call Summary for Q3/2025
- Eton Pharmaceuticals reported Q3 2025 EPS of $0.04, missing forecasts by 63.64%, while revenue exceeded expectations at $22.5 million, up 129% year-over-year
- The company achieved its 19th consecutive quarter of sequential product revenue growth, driven by strong performance from Alkindi Sprinkle, Increlex, and Galzin
- Despite the EPS miss, Eton's stock rose 1.3% in after-hours trading to $19.50, with the company reporting $12 million in operating cash flow and $37.1 million in reserves
- Eton expects gross margins to reach 70% in Q4 2025 and targets over 75% by 2028, with plans for at least two product launches in 2026
- CEO Sean Brynjelsen called 2025 'transformational,' as the company explores acquisitions in ultra-rare diseases while maintaining confidence in its orphan drug pricing power
Last Updated: 2025-11-06, 05:24 p/m
Read Full TranscriptCompare ETON to Peers and Sector
Metrics to compare | ETON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipETONPeersSector | |
|---|---|---|---|---|
P/E Ratio | −61.8x | −6.2x | −0.6x | |
PEG Ratio | 2.79 | 0.18 | 0.00 | |
Price/Book | 17.8x | 1.3x | 2.6x | |
Price / LTM Sales | 5.9x | 2.8x | 3.3x | |
Upside (Analyst Target) | 91.2% | 91.0% | 45.0% | |
Fair Value Upside | Unlock | −0.8% | 6.5% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 30.000
(+94.93% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
0.04 / 0.11
Revenue / Forecast
22.50M / 20.27M
People Also Watch
FAQ
What Is the Eton Pharmaceuticals (ETON) Stock Price Today?
The Eton Pharmaceuticals stock price today is 15.390
What Stock Exchange Does Eton Pharmaceuticals Trade On?
Eton Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Eton Pharmaceuticals?
The stock symbol for Eton Pharmaceuticals is "ETON."
What Is the Eton Pharmaceuticals Market Cap?
As of today, Eton Pharmaceuticals market cap is 412.72M.
What Is Eton Pharmaceuticals's Earnings Per Share (TTM)?
The Eton Pharmaceuticals EPS (TTM) is -0.26.
When Is the Next Eton Pharmaceuticals Earnings Date?
Eton Pharmaceuticals will release its next earnings report on Mar 12, 2026.
From a Technical Analysis Perspective, Is ETON a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Eton Pharmaceuticals Stock Split?
Eton Pharmaceuticals has split 0 times.
How Many Employees Does Eton Pharmaceuticals Have?
Eton Pharmaceuticals has 31 employees.
What is the current trading status of Eton Pharmaceuticals (ETON)?
As of Feb 04, 2026, Eton Pharmaceuticals (ETON) is trading at a price of 15.390, with a previous close of 15.390. The stock has fluctuated within a day range of 15.125 to 15.631, while its 52-week range spans from 11.087 to 23.000.
What Is Eton Pharmaceuticals (ETON) Price Target According to Analysts?
The average 12-month price target for Eton Pharmaceuticals is USD30.000, with a high estimate of USD35 and a low estimate of USD26. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +94.93% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.